Roche will pay $74 a share for InterMune, which represents a 38% premium to Friday's closing price of $53.80, in an all-cash deal. The acquisition pushed multiple biotech stocks higher Monday and that upward momentum continued Tuesday.
Deutsche Bank's Robyn Karnauskas told CNBC's Fast Money on Monday that Arrowhead is a takeout target with 100% upside in the next six months.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Arrowhead was up 15.25% to $15.49 at 2:23 p.m. More than 6.8 million shares had changed hands, compared to the average volume of 2,709,760. ARWR data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts